- DevelopersProvides clearer, more predictable Medicare reimbursement for algorithm-based medical software, which supporters say wi…
- Potential benefitLikely increases private and public investment in AI/ML medical device development by improving revenue certainty durin…
- Potential benefitMay accelerate clinical adoption of algorithm-based diagnostics and decision-support tools in hospital outpatient setti…
Health Tech Investment Act
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill (Health Tech Investment Act) amends section 1833(t) of the Social Security Act to establish special Medicare Hospital Outpatient Prospective Payment System (OPPS) rules for certain algorithm-based healthcare services. It requires the Secretary of HHS to assign algorithm-based services (defined as FDA-cleared/approved devices using AI/ML-like software) to a new technology ambulatory payment classification (APC) based on costs submitted by the manufacturer (including invoice, subscription, clinical staff, overhead) and to maintain that classification for at least five years unless adequate claims data justify reassignment.
Trust in manufacturer-provided cost data: liberals and centrists want independent verification; conservatives emphasize fiscal limits and market controls.
Relative to its intended legislative type, this bill establishes a clear statutory change to Medicare hospital outpatient payment rules to cover certain algorithm-based services, provides concrete definitional and assignment language, and identifies the implementing agency and effective dates, but leaves important procedural, fiscal, and accountability details to future agency action without statutory guidance.
The bill (Health Tech Investment Act) amends section 1833(t) of the Social Security Act to establish special Medicare Hospital Outpatient Prospective Payment System (OPPS) rules for certain algorithm-based healthcare services.
It requires the Secretary of HHS to assign algorithm-based services (defined as FDA-cleared/approved devices using AI/ML-like software) to a new technology ambulatory payment classification (APC) based on costs submitted by the manufacturer (including invoice, subscription, clinical staff, overhead) and to maintain that classification for at least five years unless adequate claims data justify reassignment.
The bill directs the Secretary to adjust NT APC application criteria so adjunctive or concurrently furnished algorithm services that require additional resources can qualify.
Content-wise, this is a plausible administrative/technical fix that aligns with industry and provider interests and clarifies payment rules for emerging AI-based services — factors that increase chances of enactment. Countervailing factors include likely attention to Medicare budgetary impacts, lack of explicit offsets, and administrative complexity in implementing manufacturer cost submissions and validation. Such measures frequently succeed when attached to larger bipartisan packages that address offsets or as part of committee-level consensus, but stand-alone passage faces moderate barriers.
Relative to its intended legislative type, this bill establishes a clear statutory change to Medicare hospital outpatient payment rules to cover certain algorithm-based services, provides concrete definitional and assignment language, and identifies the implementing agency and effective dates, but leaves important procedural, fiscal, and accountability details to future agency action without statutory guidance.
Trust in manufacturer-provided cost data: liberals and centrists want independent verification; conservatives emphasize fiscal limits and market controls.
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Federal agenciesMay increase Medicare spending if payments are set on manufacturer-reported invoice or subscription prices rather than…
- ManufacturersRisk of inflated or non-comparable cost submissions from manufacturers leading to overpayment, because the bill priorit…
- Potential burdenLocks payments for a minimum period and shifts evaluation away from claims-based evidence, which critics may say reduce…
Why the argument around this bill splits.
Trust in manufacturer-provided cost data: liberals and centrists want independent verification; conservatives emphasize fiscal limits and market controls.
A mainstream progressive would see strengths in clarifying Medicare payment for AI-driven clinical tools, which could expand access to beneficial diagnostic or treatment support technologies.
However, they would be concerned that relying primarily on manufacturer-submitted costs and protecting new-technology classification for at least five years risks overpayment, lack of price transparency, and insufficient safeguards against gaming.
They would want stronger oversight, price verification, equity safeguards (to ensure rural and safety-net providers benefit), and patient-safety protections tied to payment.
A pragmatic centrist would appreciate the bill’s attempt to provide predictable Medicare payment for new kinds of software-driven services and to update OPPS policy for modern pricing models (subscription/SaaS).
They would see potential benefits for innovation and hospital budgeting, but worry about fiscal exposure and insufficient detail on cost verification, monitoring, and sunset/review mechanisms.
They would favor the underlying goal of aligning payment policy with current technology while seeking amendments to strengthen transparency, auditability, and budget controls.
A mainstream conservative would be split: they may welcome measures that clarify payment for innovative private-sector technologies and recognize market pricing models (like subscriptions), which can support private innovation.
At the same time, they would be wary of any new policy that potentially expands Medicare spending or creates federal mandates that favor particular technologies or vendors without strong price controls.
The provision that relies on manufacturer-submitted costs and effectively locks in a payment classification for at least five years could be seen as increasing federal exposure to higher prices.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise, this is a plausible administrative/technical fix that aligns with industry and provider interests and clarifies payment rules for emerging AI-based services — factors that increase chances of enactment. Countervailing factors include likely attention to Medicare budgetary impacts, lack of explicit offsets, and administrative complexity in implementing manufacturer cost submissions and validation. Such measures frequently succeed when attached to larger bipartisan packages that address offsets or as part of committee-level consensus, but stand-alone passage faces moderate barriers.
- No cost estimate (CBO/ARC) is included in the text; the fiscal magnitude of increased payments to Medicare from these rules is unknown and would heavily influence floor and conference negotiations.
- Implementation details are delegated to the Secretary (forms, verification of manufacturer-submitted costs, treatment of subscription pricing), and administrative feasibility and auditability of manufacturer cost claims are uncertain.
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Trust in manufacturer-provided cost data: liberals and centrists want independent verification; conservatives emphasize fiscal limits and m…
Content-wise, this is a plausible administrative/technical fix that aligns with industry and provider interests and clarifies payment rules…
Relative to its intended legislative type, this bill establishes a clear statutory change to Medicare hospital outpatient payment rules to cover certain algorithm-based services, provides concrete definitional and assig…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.